Cardiology Training Day - Arrhythmias, Electrophysiology and Devices - 22nd November 2011
Endobronchial & Endoscopic Ultrasound EBUS Course - Thursday 24th & Friday 25th November 2011
Transplant and Lung Failure Symposium - 23rd March 2012
Papworth ECMO Course - 26th, 27th & 28th March 2012
(COMMENT: Still no Press release about the Papworth doctors who saved Prince Philip's life)
29 December 2011
28 December 2011
ROYAL ROLE in UK MEDICAL TRAVEL TOURISM
The UK Royal Family are consumer models for the UK Middle and Upper Middle classes. There are approx 850 ROYAL WARRENT HOLDERS including BOOTS the CHEMIST. Medical practitioners are rewarded for services to the Royal Family by membership in the ROYAL VICTORIAN ORDER
Hospitals can be elevated by the addition of ROYAL such as ROYAL BROMPTON (Lungs & Heart), ROYAL FREE (first to admit female students), ROYAL London Hosp for INTEGRATED MEDICINE,(originally Royal Homoeopathic), ROYAL LONDON (East End), ROYAL MARSDEN (Cancer) and some community hospitals such as Guildford's Royal Surrey County Hosp.
UK Medicine is an important invisible EXPORT. PRIVATE medicine has been alive & well since the beginning of the NHS in 1947. Teaching hospitals have PRIVATE wards. There are many PRIVATE HOSPITALS including the Royal favourite , the London KING EDWARD VII Hosp for Officers (public accepted - military families pay reduced fees), the famous (1932,) Harley Street, LONDON CLINIC.and the (1975) WELLINGTON HOSP ,(overlooking Lord's Cricket Ground), now owned by Nashville,USA, HCA Holdings Inc which also owns the ALL PRIVATE Harley Street Clinic, Lister Hosp., London Bridge Hosp.,Portland Hosp. (women/children), and the Princess Grace Hosp.
Hopefully the PAPWORTH HOSPITAL doctors who saved the life of Prince Philip will be named by the Palace Press office. This would encourage Medical Travel tourism to the clean air of the village of Papworth Everard., 10 miles West of Cambridge (45 min by train from London). It would also be interesting to the World's medical profession to know what brand of STENT was used.
Hospitals can be elevated by the addition of ROYAL such as ROYAL BROMPTON (Lungs & Heart), ROYAL FREE (first to admit female students), ROYAL London Hosp for INTEGRATED MEDICINE,(originally Royal Homoeopathic), ROYAL LONDON (East End), ROYAL MARSDEN (Cancer) and some community hospitals such as Guildford's Royal Surrey County Hosp.
UK Medicine is an important invisible EXPORT. PRIVATE medicine has been alive & well since the beginning of the NHS in 1947. Teaching hospitals have PRIVATE wards. There are many PRIVATE HOSPITALS including the Royal favourite , the London KING EDWARD VII Hosp for Officers (public accepted - military families pay reduced fees), the famous (1932,) Harley Street, LONDON CLINIC.and the (1975) WELLINGTON HOSP ,(overlooking Lord's Cricket Ground), now owned by Nashville,USA, HCA Holdings Inc which also owns the ALL PRIVATE Harley Street Clinic, Lister Hosp., London Bridge Hosp.,Portland Hosp. (women/children), and the Princess Grace Hosp.
Hopefully the PAPWORTH HOSPITAL doctors who saved the life of Prince Philip will be named by the Palace Press office. This would encourage Medical Travel tourism to the clean air of the village of Papworth Everard., 10 miles West of Cambridge (45 min by train from London). It would also be interesting to the World's medical profession to know what brand of STENT was used.
23 December 2011
Sir (Dr.) Pendrill VARRIER-JONES (1883-1941) & PAPWORTH HOSPITAL
In 1918, the Cambridgeshire Tuberculosis Colony, consisting of 17 patients, moved from the nearby village of Bourn into Papworth Hall, which was vacant following (financier) Ernest Hooley's departure. This event was to have a profound effect on the future of the village. With the Hall went the village and most of the land in the parish. Under the energetic and capable management of Dr (later, Sir) Pendrill Varrier-Jones the Papworth Colony rapidly expanded. (In the early twentieth century, before effective drug treatments became available, TB was not only a potential killer for the victim but also had devastating consequences for the whole family who were often evicted from their home, sacked from their employment and generally ostracised from friends, family and community).
Although there were still many deaths among tuberculosis patients, even at Papworth, the aim was to rehabilitate sufferers by arresting their disease, by giving them appropriate work, and by allowing their families to come and live in the village with them. Papworth ultimately offered free medical care, excellent housing, schools, recreation and a chance for the TB patient to rebuild their life.
The Hall soon became too small and a new hospital was built in the grounds. In all, about 300 new houses were built for TB patients and their families, first along Ermine Street and then on the Pendragon Hill/Ridgeway Estate. Baron's Way, to the East of the playing fields, was built in the early 1950's. Factory buildings were constructed in the 1930's - replacing earlier workshops - and a shop was provided.
During the 1940s antibiotics became available that would cure TB. In the late 1940's, the hospital passed to the newly formed National Health Service and became the East Anglian centre for chest and heart medicine and much pioneering work has been done. Papworth was one of the very first hospitals in the country to undertake open-heart surgery and in 1978 Sir Terrance English undertook the first of the current series of successful heart transplants in Britain. Later, the first combined heart and lung transplant in Europe was carried out at Papworth.
COMMENT:
Papworth Hospital is to be rebuilt in Cambridge by the combined firms of BOUYGUES SA in Paris and SKANSKA AB in Solna.
Papworth also takes PAYING PATIENTS.
Although there were still many deaths among tuberculosis patients, even at Papworth, the aim was to rehabilitate sufferers by arresting their disease, by giving them appropriate work, and by allowing their families to come and live in the village with them. Papworth ultimately offered free medical care, excellent housing, schools, recreation and a chance for the TB patient to rebuild their life.
The Hall soon became too small and a new hospital was built in the grounds. In all, about 300 new houses were built for TB patients and their families, first along Ermine Street and then on the Pendragon Hill/Ridgeway Estate. Baron's Way, to the East of the playing fields, was built in the early 1950's. Factory buildings were constructed in the 1930's - replacing earlier workshops - and a shop was provided.
During the 1940s antibiotics became available that would cure TB. In the late 1940's, the hospital passed to the newly formed National Health Service and became the East Anglian centre for chest and heart medicine and much pioneering work has been done. Papworth was one of the very first hospitals in the country to undertake open-heart surgery and in 1978 Sir Terrance English undertook the first of the current series of successful heart transplants in Britain. Later, the first combined heart and lung transplant in Europe was carried out at Papworth.
COMMENT:
Papworth Hospital is to be rebuilt in Cambridge by the combined firms of BOUYGUES SA in Paris and SKANSKA AB in Solna.
Papworth also takes PAYING PATIENTS.
22 December 2011
GP Behnaz YAZDANFAR found GUILTY. Will CPSO REGISTRAR GERACE RESIGN?
from TORONTO STAR
(Real estate agent) Krista Tabacoff Stryland, (1974-2007) was pronounced dead in North York Hosp shortly after paramedics took her there from GP Behnaz Yazdanfar’s cosmetic clinic (in a North Toronto office building).
The GP who was found incompetent in her care of cosmetic surgery patients – including Ms STRYLAND who died following a SIX LITER liposuction in 2007 .
Dr. Behnaz Yazdanfar was found to have displayed “disgraceful, dishonourable or unprofessional” conduct in her care of five patients following a TWO YEAR disciplinary hearing before the Ontario College of Physicians and Surgeons that ended in May 2011. PENALTY delayed for SEVEN MONTHS..
Yesterday the college suspended Yazdanfar’s licence for two years. After that, Dr. Yazdanfar will be restricted from SOLO surgery but will be permitted to ASSIST in surgery, including cosmetic procedures.
She was ordered Wednesday to appear before the college for a public reprimand within the next three months.
Yazdanfar was ordered to pay $219,000 in costs to the college within a year.
She must also co-operate with unannounced inspections of her practice and patient charts, conducted at her expense, and publish the terms of her restrictions at her clinic and on her website.
Like many doctors performing cosmetic procedures (in Ontario), Dr. Yazdanfar was never accredited as a plastic surgeon and holds no surgical designation.
Ms. Krista Stryland was pronounced dead in hospital shortly after paramedics took her from Dr.Yazdanfar’s cosmetic clinic. Court records obtained by the Star alleged Ms. Stryland lay in the clinic’s recovery room in serious condition for 30 minutes before anyone called 911.
Dr. Bruce Liberman, the anesthesiologist in the Stryland case, was also found to be incompetent. He is awaiting the result of a separate disciplinary hearing.
COMMENTS:
The CPSO was aware that GPs were perfoming surgery under GENERAL ANAESTHESIA in office buildings. The CPSO Registrar, past ER physician & CPSO Past President, , R.V. GERACE MD (UWO 72) FRCSC (ER 83) was aware of the danger for years and took no preventive action. As a direct result of this negligence a patient died; will Dr.Gerace resign?
Dr.Yazdanfar was represented by Lawyers Clayton Ruby CM BA(York 63) LLB (Tor.69) LLM(U.Cal.Berkeley) 11 Prince Arthur Av.,Yorkville,Tor. & Gardiner Roberts LLP partner Tracey Tremayne-Lloyd LLB( 83) Certificate in Health Law, They did a superb job: Dr. Yazdanfar did NOT lose her licence. Only a nominal "Suspension" for 2 years: no problem as the clinic can function withoout her medical services employing other doctors. Also Dr.Yazdanfar can do admin. duties. As for the CPSO legal costs of $219,000 (NOT A FINE) , this a moderate amount considering the gravity of the case. Also is TAX DEDUCTABLE.
(Real estate agent) Krista Tabacoff Stryland, (1974-2007) was pronounced dead in North York Hosp shortly after paramedics took her there from GP Behnaz Yazdanfar’s cosmetic clinic (in a North Toronto office building).
The GP who was found incompetent in her care of cosmetic surgery patients – including Ms STRYLAND who died following a SIX LITER liposuction in 2007 .
Dr. Behnaz Yazdanfar was found to have displayed “disgraceful, dishonourable or unprofessional” conduct in her care of five patients following a TWO YEAR disciplinary hearing before the Ontario College of Physicians and Surgeons that ended in May 2011. PENALTY delayed for SEVEN MONTHS..
Yesterday the college suspended Yazdanfar’s licence for two years. After that, Dr. Yazdanfar will be restricted from SOLO surgery but will be permitted to ASSIST in surgery, including cosmetic procedures.
She was ordered Wednesday to appear before the college for a public reprimand within the next three months.
Yazdanfar was ordered to pay $219,000 in costs to the college within a year.
She must also co-operate with unannounced inspections of her practice and patient charts, conducted at her expense, and publish the terms of her restrictions at her clinic and on her website.
Like many doctors performing cosmetic procedures (in Ontario), Dr. Yazdanfar was never accredited as a plastic surgeon and holds no surgical designation.
Ms. Krista Stryland was pronounced dead in hospital shortly after paramedics took her from Dr.Yazdanfar’s cosmetic clinic. Court records obtained by the Star alleged Ms. Stryland lay in the clinic’s recovery room in serious condition for 30 minutes before anyone called 911.
Dr. Bruce Liberman, the anesthesiologist in the Stryland case, was also found to be incompetent. He is awaiting the result of a separate disciplinary hearing.
COMMENTS:
The CPSO was aware that GPs were perfoming surgery under GENERAL ANAESTHESIA in office buildings. The CPSO Registrar, past ER physician & CPSO Past President, , R.V. GERACE MD (UWO 72) FRCSC (ER 83) was aware of the danger for years and took no preventive action. As a direct result of this negligence a patient died; will Dr.Gerace resign?
Dr.Yazdanfar was represented by Lawyers Clayton Ruby CM BA(York 63) LLB (Tor.69) LLM(U.Cal.Berkeley) 11 Prince Arthur Av.,Yorkville,Tor. & Gardiner Roberts LLP partner Tracey Tremayne-Lloyd LLB( 83) Certificate in Health Law, They did a superb job: Dr. Yazdanfar did NOT lose her licence. Only a nominal "Suspension" for 2 years: no problem as the clinic can function withoout her medical services employing other doctors. Also Dr.Yazdanfar can do admin. duties. As for the CPSO legal costs of $219,000 (NOT A FINE) , this a moderate amount considering the gravity of the case. Also is TAX DEDUCTABLE.
KOREAN-CANADIAN VENTURE for AIDS VACCINE
Sumagen Canada Inc. is a solely owned subsidiary of Sumagen Co., Ltd.
Sumagen Co., Ltd is a Korean pharmaceutical venture company focusing on developing an HIV/AIDS vaccine and is a solely owned subsidiary of Curocom Co., Ltd. Sumagen is also supporting the ongoing research work at the Schulich School of Medicine and Dentistry, The University of Western Ontario (UWO) for and HCV (Hepatitis C Viru) vaccine.
Dr. Chil Yong Kang, Sumagen's Chief Scientific Officer and also a professor at UWO, developed a vaccine for HIV/AIDS for both therapeutic and prophylactic use with his team. In 2006, the company opened an office in London at the Stiller Centre, in order to closely support the vaccine development. The office in London with a staff of six, are managing the project to manufacture the materials for clinical trials, conduct non-clinical studies, and coordinate through a consultant to meet the requirements of the FDA in the United States to obtain approval to conduct human clinical trials.
Sumagen Co., Ltd is a Korean pharmaceutical venture company focusing on developing an HIV/AIDS vaccine and is a solely owned subsidiary of Curocom Co., Ltd. Sumagen is also supporting the ongoing research work at the Schulich School of Medicine and Dentistry, The University of Western Ontario (UWO) for and HCV (Hepatitis C Viru) vaccine.
Dr. Chil Yong Kang, Sumagen's Chief Scientific Officer and also a professor at UWO, developed a vaccine for HIV/AIDS for both therapeutic and prophylactic use with his team. In 2006, the company opened an office in London at the Stiller Centre, in order to closely support the vaccine development. The office in London with a staff of six, are managing the project to manufacture the materials for clinical trials, conduct non-clinical studies, and coordinate through a consultant to meet the requirements of the FDA in the United States to obtain approval to conduct human clinical trials.
19 December 2011
USA C.A.P. MALIGNANT MELANOMA & ZELBORAF
Anne Paxton
Take a fatal and nearly untreatable cancer. Invest hundreds of millions of dollars to develop and test a drug that shrinks tumors or improves survival in half of patients with a common mutation. Link diagnosis to a PCR test that you also manufacture. And win an accelerated FDA approval for the test-drug combination.
Altogether, no mean feat. And it’s essentially what Roche accomplished to bring its metastatic melanoma drug Zelboraf (vemurafenib) on the market this year.
By all accounts, Zelboraf should bring new hope to thousands of melanoma patients and perhaps a billion dollars a year in revenue to Roche. “It’s the first ever joint FDA approval of a drug and a DNA-based companion diagnostic, and the beginning of the molecular companion diagnostics era,” says John W. Longshore, PhD, director of molecular pathology for Carolinas Pathology Group, Carolinas Medical Center, Charlotte, NC.
The FDA, in its approach to companion diagnostics, seems to favor single-assay platforms while the field moves toward multiplexed platforms, says Dr. Marc Ladanyi, here at Memorial Sloan-Kettering Cancer Center with colleagues involved in BRAF mutation testing, Maria Arcila, MD (center), and Laetitia Borsu, PhD.
Zelboraf, a kinase inhibitor, has been proven effective only for melanoma patients with the BRAF V600E mutation. But the linkage of Zelboraf to the Roche Cobas 4800 BRAF V600 Mutation Test is creating something of a furor. In its Aug. 17 approval of Zelboraf, the FDA’s Center for Drug Evaluation and Research specified that the drug is indicated “for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test” (emphasis added). So when the FDA Center for Devices and Radiological Health granted pre-market approval for the Cobas test the same day, the Roche assay became the de facto companion diagnostic for Zelboraf.
Take a fatal and nearly untreatable cancer. Invest hundreds of millions of dollars to develop and test a drug that shrinks tumors or improves survival in half of patients with a common mutation. Link diagnosis to a PCR test that you also manufacture. And win an accelerated FDA approval for the test-drug combination.
Altogether, no mean feat. And it’s essentially what Roche accomplished to bring its metastatic melanoma drug Zelboraf (vemurafenib) on the market this year.
By all accounts, Zelboraf should bring new hope to thousands of melanoma patients and perhaps a billion dollars a year in revenue to Roche. “It’s the first ever joint FDA approval of a drug and a DNA-based companion diagnostic, and the beginning of the molecular companion diagnostics era,” says John W. Longshore, PhD, director of molecular pathology for Carolinas Pathology Group, Carolinas Medical Center, Charlotte, NC.
The FDA, in its approach to companion diagnostics, seems to favor single-assay platforms while the field moves toward multiplexed platforms, says Dr. Marc Ladanyi, here at Memorial Sloan-Kettering Cancer Center with colleagues involved in BRAF mutation testing, Maria Arcila, MD (center), and Laetitia Borsu, PhD.
Zelboraf, a kinase inhibitor, has been proven effective only for melanoma patients with the BRAF V600E mutation. But the linkage of Zelboraf to the Roche Cobas 4800 BRAF V600 Mutation Test is creating something of a furor. In its Aug. 17 approval of Zelboraf, the FDA’s Center for Drug Evaluation and Research specified that the drug is indicated “for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test” (emphasis added). So when the FDA Center for Devices and Radiological Health granted pre-market approval for the Cobas test the same day, the Roche assay became the de facto companion diagnostic for Zelboraf.
Late Maj Dr. R.G.GAYER-ANDERSON DSO RAMC PASHA
Detail of the headThe sculpture is now known as the Gayer-Anderson cat after Major Robert Grenville Gayer-Anderson who donated it, together with Mary Stout Shaw, to the British Museum.[1] The statue is a representation of the cat-goddess Bastet. The cat wears jewellery and a protective wedjat amulet. The earrings and nose ring on the statue may not have always belonged to the cat.[2] While they certainly are ancient, an early photograph of the cat shows the statue wearing a different pair. A winged scarab appears on the chest and head, it is 42cm high and 13cm wide. A copy of the statue is kept in the Gayer-Anderson Museum, located in Cairo.
ConstructionThe statue is not as well preserved as it appears. X-Rays taken of the sculptire reveal that there are cracks that extend almost completely around the centre of the cats body and only an internal system of strengthening prevents the cat's head from falling off. The repairs to the cat are thought to have been carried out by Major Gayer-Anderson who was a keen restorer of antiquities in the 1930s. He is thought to have rediscovered the surface of the cat after the presumed corrosion had been removed.[3]
The cat was manufactured by the lost wax method where a wax model is covered with clay or clay and water until there is sufficient thickness. The clay can then be fired in a kiln and the wax flows out. The now hollow mould can be refilled with bronze. In this case the metal was 85% copper, 13% tin, 2% arsenic with a 0.2% trace of lead. The remains of the pins that held the wax core can still be seen using x-rays. The original metalworkers would have been able to create a range of colours on a bronze casting and the stripes on the tail are due to metal of a differeing composition. It is also considered likely that the eyes contained stone or glass decorations.[3]
[edit] References^ Description of the Gayer-Anderson Cat, British Museum
^ Oakes, Lorna, and Lucia Gahlin. Ancient Egypt: An Illustrated Reference to the Myths, Religions, Pyramids and Temples of the Land of the Pharaohs. (p. 229) Barnes & Noble, September 2003. ISBN 9780760749432.
^ a b Examination of the Gayer-Anderson cat, British Museum, accessed December 2010
[edit] Further readingClutton-Brock, J. The British Museum book of Cat. London: The British Museum Press, 2000.
Warner, Nicholas. Guide to the Gayer-Anderson Museum, Cairo. Cairo: Press of the Supreme Council of Antiquities, 2003.
Dr.Gayer-Anderson donated his Cairo home to the Egyptian Government. King Farouk awarded him the Title of PASHA.
Returned to WATERBEACH near Cambridge. Son John; a Ceramic artist.
ConstructionThe statue is not as well preserved as it appears. X-Rays taken of the sculptire reveal that there are cracks that extend almost completely around the centre of the cats body and only an internal system of strengthening prevents the cat's head from falling off. The repairs to the cat are thought to have been carried out by Major Gayer-Anderson who was a keen restorer of antiquities in the 1930s. He is thought to have rediscovered the surface of the cat after the presumed corrosion had been removed.[3]
The cat was manufactured by the lost wax method where a wax model is covered with clay or clay and water until there is sufficient thickness. The clay can then be fired in a kiln and the wax flows out. The now hollow mould can be refilled with bronze. In this case the metal was 85% copper, 13% tin, 2% arsenic with a 0.2% trace of lead. The remains of the pins that held the wax core can still be seen using x-rays. The original metalworkers would have been able to create a range of colours on a bronze casting and the stripes on the tail are due to metal of a differeing composition. It is also considered likely that the eyes contained stone or glass decorations.[3]
[edit] References^ Description of the Gayer-Anderson Cat, British Museum
^ Oakes, Lorna, and Lucia Gahlin. Ancient Egypt: An Illustrated Reference to the Myths, Religions, Pyramids and Temples of the Land of the Pharaohs. (p. 229) Barnes & Noble, September 2003. ISBN 9780760749432.
^ a b Examination of the Gayer-Anderson cat, British Museum, accessed December 2010
[edit] Further readingClutton-Brock, J. The British Museum book of Cat. London: The British Museum Press, 2000.
Warner, Nicholas. Guide to the Gayer-Anderson Museum, Cairo. Cairo: Press of the Supreme Council of Antiquities, 2003.
Dr.Gayer-Anderson donated his Cairo home to the Egyptian Government. King Farouk awarded him the Title of PASHA.
Returned to WATERBEACH near Cambridge. Son John; a Ceramic artist.
Subscribe to:
Posts (Atom)